The federal drug shortage crisis keeps getting worse, with 227 medications now in short supply across the country and the typical shortage dragging on for five years before it resolves.
The Food and Drug Administration recently added 12 new medications to its drug shortage database, a rolling list updated daily that tracks medicines Americans cannot reliably find at their pharmacies. The additions include insulin products, a diabetes injection, a heart rhythm drug, cancer treatments, and a hormone therapy, covering conditions that affect tens of millions of patients nationwide.
The American Society of Health-System Pharmacists reported that drug shortages climbed again in 2026, marking the third consecutive quarterly increase. That steady deterioration has pushed the total number of active shortages to 227, The US Sun reported. And the problem does not resolve quickly. Becker's Hospital Review found that the median duration of a drug shortage rose in 2025 to five years, meaning patients who lose access to a medication today may not see reliable supply again until 2030.
The 12 newly listed shortages trace to a concentrated burst of manufacturer discontinuations between August 24 and September 1. Nearly half of the new shortages came from a single manufacturer, though the FDA database does not identify which one.
Pfizer moved first. On August 24, the company discontinued the 100-milligram and 150-milligram extended-release capsules of disopyramide phosphate, a drug used to treat irregular heartbeats. A week later, on August 31, Pfizer pulled its 2.5-milligram and 10-milligram tablets of medroxyprogesterone acetate, a hormone therapy prescribed for conditions ranging from abnormal uterine bleeding to certain cancers.
Novo Nordisk discontinued its liraglutide injection, a diabetes medication, on August 25. The drug will not be fully removed from the market until January 2027, but the discontinuation means new supply has already stopped.
Eli Lilly followed on September 1 by discontinuing three insulin products at once: insulin glargine-aglr injection, insulin lispro injection, and insulin lispro protamine and insulin lispro injection. The company cited a business decision as the reason. Distribution of those three drugs is expected to continue winding down through June 2027.
That phrase, "business decision", appeared more than once. Several strengths of metoprolol succinate, an extended-release blood pressure and heart medication available in 25-, 50-, 100-, and 200-milligram tablets, were also discontinued for the same stated reason. No manufacturer was named for that particular drug.
Not every shortage on the list stems from a corporate exit. Pentostatin injection, an oncology drug distributed by Hospira, a Pfizer-owned company, landed on the shortage list because of manufacturing delays. The FDA does not expect supply to recover until 2027.
Earlier in August, shortages of two other cancer drugs, cisplatin and carboplatin, had already been reported, adding to the strain on oncology treatment nationwide.
Fresenius Kabi discontinued its injection solution combining potassium chloride, sodium chloride, calcium chloride, and magnesium chloride on August 31. These electrolyte solutions are used in hospitals for patients who cannot take fluids by mouth. Amgen discontinued glycerol phenylbutyrate oral liquid, a treatment for a rare metabolic disorder, on September 1.
Two other drugs rounded out the list. A 2.5-milligram capsule of palovarotene was discontinued August 31, and a 0.375-milligram extended-release capsule of mesalamine, used to treat inflammatory bowel disease, was discontinued August 25. Neither discontinuation named a manufacturer.
The new additions land on top of an already strained system. An ongoing shortage of certain ADHD medications was reported as far back as April, and the FDA has not indicated that those shortages have been resolved. For parents trying to fill prescriptions for children, or adults managing the condition to hold down jobs, months of uncertainty have become the norm.
The pattern is clear enough in the numbers. Three straight quarters of rising shortages. A median resolution time that now stretches half a decade. Major manufacturers walking away from product lines and calling it a "business decision" while patients scramble for alternatives.
The FDA maintains its database as a public resource, updated daily, so Americans can check which medications are affected. But a database is not a solution. It tells patients what they already know when they leave the pharmacy empty-handed.
When the biggest drug companies in the world can drop essential medications, insulin, heart drugs, cancer treatments, and the federal government's only visible response is updating a spreadsheet, the system is not working for the people it is supposed to protect.